Form 4: Aquestive Therapeutics CEO Daniel Barber Reports Tax-Related Stock Transaction
SEC Form 4 Filing
Daniel Barber, CEO of Aquestive Therapeutics, reports a transaction involving the withholding of shares to cover tax obligations related to vested Restricted Stock Units.
Summary
- On March 9, 2024, Daniel Barber, the President and CEO of Aquestive Therapeutics, Inc. (AQST), had 37,938 shares of common stock withheld by the issuer to satisfy tax obligations.
- This transaction was related to the vesting of previously granted Restricted Stock Units (RSUs).
- Following the transaction, Barber directly owns 845,364 shares of Aquestive Therapeutics common stock.
Sentiment
Score: 5
Explanation: The filing reflects a routine transaction (tax withholding) and doesn't inherently indicate positive or negative sentiment regarding the company's prospects.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This transaction is a standard tax-related event associated with RSU vesting.
Stakeholder Impact
- The transaction has a minimal direct impact on stakeholders, as it is a standard tax-related event.
Key Dates
| Date | Description |
|---|---|
| 03/09/2024 | Date of stock transaction (tax withholding). |
| 03/12/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.